bbln-20230510

0001866390-23-000084.txt : 20230510 0001866390-23-000084.hdr.sgml : 20230510 20230510060056 ACCESSION NUMBER: 0001866390-23-000084 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230510 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230510 DATE AS OF CHANGE: 20230510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Babylon Holdings Ltd CENTRAL INDEX KEY: 0001866390 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40952 FILM NUMBER: 23904138 BUSINESS ADDRESS: STREET 1: 2500 BEE CAVE ROAD STREET 2: BLDG 1, STE 400 CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: 512-967-3787 MAIL ADDRESS: STREET 1: 2500 BEE CAVE ROAD STREET 2: BLDG 1, STE 400 CITY: AUSTIN STATE: TX ZIP: 78746 8-K 1 bbln-20230510.htm 8-K bbln-20230510

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

May 10, 2023

Date of Report (date of earliest event reported)

___________________________________

Babylon Holdings Limited

(Exact name of registrant as specified in its charter)

___________________________________


Bailiwick of Jersey, Channel Islands (State or other jurisdiction of incorporation)	001-40952 (Commission File Number)	98-1638964 (IRS Employer Identification No.)
2500 Bee Cave Road Building 1 - Suite 400 Austin, TX		78746
(Address of principal executive offices)		(Zip Code)
(512) 967-3787
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A ordinary shares, par value $0.001056433113 per share	BBLN	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

Amended and Restated Bridge Facility Agreement

On May 10, 2023, Babylon Holdings Limited (“Babylon” or the “Company” and, together with its consolidated subsidiaries, the “Group”), the Subsidiary Guarantors (as defined below), and certain AlbaCore Bridge Notes Subscribers (as defined below) entered into an amendment and restatement agreement (the “Amendment and Restatement Agreement”) to that certain bridge loan notes facility agreement, dated March 9, 2023 (the “Bridge Facility Agreement,” and as amended and restated, the “Amended Bridge Facility Agreement”), by and among the Company, as borrower, Babylon Healthcare Inc., Babylon Partners Ltd., and Babylon Inc., as subsidiary guarantors (the “Subsidiary Guarantors”), Babylon Group Holdings Limited, a limited company organized under the laws of England, as parent guarantor (the “Parent Guarantor” and, together with the Subsidiary Guarantors, the “Guarantors”), and certain affiliates of, or funds managed and/or advised by, AlbaCore Capital LLP (the “AlbaCore Bridge Notes Subscribers”).

Pursuant to the initial Bridge Facility Agreement, the AlbaCore Bridge Notes Subscribers provided Babylon with secured debt financing in the form of a senior secured term loan notes facility (the “Bridge Facility”) for an aggregate principal amount of up to $34,500,000 (such loan notes, the “Bridge Notes”). The Bridge Facility was subject to an original issue discount (calculated on the basis of an aggregate principal amount of $30,000,000). The Bridge Notes were issued in three tranches.

On April 17, 2023, the Company and the note trustee under the Bridge Facility (the “Note Trustee”) agreed to a waiver of the conditions for the utilization of tranche three of the Bridge Facility (the “Tranche Three Waiver”). In connection with the Tranche Three Waiver, among other things, (i) certain operational milestones under the Bridge Facility Agreement were extended, (ii) the governance regime agreed under the Bridge Facility Agreement was simplified to provide a right for certain noteholders under the Bridge Facility (the “Bridge Noteholders”) to nominate a candidate for appointment by the Company as an independent, non-executive director to the board of directors of the Company and that, following such appointment, the board of directors of the Company shall at all times comprise a maximum of five directors, a majority of which must be independent, non-executive directors and two of which must be nominated by the Bridge Noteholders and (iii) the Company agreed to provide the Bridge Noteholders with additional information in relation to the Group to facilitate their financial, operational and legal due diligence of the Group.

Pursuant to the Amended Bridge Facility Agreement, the Bridge Noteholders agreed to provide further secured debt financing in the form of an additional senior secured term loan notes facility (the “Additional Bridge Facility”) in an additional aggregate principal amount of up to $34,500,000, to be funded in three tranches (such loan notes to be issued thereunder, the “Additional Bridge Notes”). The Additional Bridge Facility is subject to an original issue discount (calculated on the basis of an aggregate principal amount of $30,000,000).

The Additional Bridge Notes will be issued by the Parent Guarantor, and are on economic terms substantially similar to the Bridge Notes and will rank pari passu with the Bridge Notes. The issuance of the Additional Bridge Notes is subject to the satisfaction of certain conditions precedent, including the receipt of certain supplemental security agreements and other transaction documentation, and with respect to the third tranche (Tranche Six, as defined below), approvals by Bridge Noteholders.

Each member of the Group which granted security to secure the obligations in respect of the Bridge Notes and the Existing Notes (as defined below) is required to grant supplementary security on substantially the same terms to secure the obligations in respect of the Additional Bridge Notes. The Additional Bridge Notes are guaranteed by the Company and the Guarantors on substantially the same terms as the guarantees granted in respect of the Bridge Notes.

The first tranche of the Additional Bridge Facility (“Tranche Four,” in an aggregate principal amount of $5,750,000, representing $5,000,000 net of original issue discount) will be provided from and including the date on which the conditions precedent in respect of Tranche Four have been satisfied or waived (the “Tranche 4 Closing Date”) until May 12, 2023 and shall be subject, among other conditions, to the public announcement by the Company disclosing the Additional Bridge Facility within four business days of the date of the Amendment and Restatement Agreement; the second tranche of the Additional Bridge Facility (“Tranche Five,” in an aggregate principal amount of $11,500,000, representing $10,000,000 net

of original issue discount) may be utilized from May 19, 2023 until June 16, 2023, subject, among other conditions, to the prior utilization in full of Tranche Four; and the third tranche of the Additional Bridge Facility (“Tranche Six,” in an aggregate principal amount of $17,250,000, representing $15,000,000 net of original issue discount) may be utilized on a date agreed between the Parent Guarantor and the Bridge Noteholders which may not be earlier than June 9, 2023 subject, among other conditions, to the prior utilization in full of Tranche Four and Tranche Five and approvals by Bridge Noteholders. Tranche Four is anticipated to be utilized on May 12, 2023, in connection with the entry into the Amended Bridge Facility Agreement and the Framework Implementation Agreement (as defined below).

The Amended Bridge Facility Agreement provides that proceeds from the Additional Bridge Facility must be used for working capital purposes and payments of fees, costs and expenses in connection with the Additional Bridge Facility and related transaction documentation. Pursuant to the terms of the Amended Bridge Facility Agreement, the Group is subject to certain additional restrictive covenants in relation to cash management, intra-group lending and certain other transactions, certain permitted exclusions to the restrictive covenants under the Bridge Facility Agreement have been removed or limited, certain events of default have been expanded to cover all members of the Group, certain additional events of default have been added to the Bridge Facility Agreement, certain additional events in relation to restrictions on transfer of the Bridge Notes and/or the Additional Bridge Notes have been added to the Bridge Facility Agreement and the operational milestones in relation to a recapitalization of the Group and/or the sale of the Group, a sale of a strategic minority stake in the Group or a sale of material assets or subsidiaries of the Group have been removed.

The economic pricing terms of the Additional Bridge Notes are substantially similar to the Bridge Notes. The Additional Bridge Notes bear PIK interest at a rate of Term SOFR plus credit adjustment spread plus a 12% margin. All PIK interest shall be capitalized and added to the principal of the Additional Bridge Facility on the interest payment date of each month, and an upfront fee of 15% of the aggregate commitments under the Additional Bridge Facility (less the aggregate of the amounts of the original issue discount and certain costs, fees and expenses) shall be deferred (and in the case of the upfront fee relating to Tranche Six shall accrue only if Tranche Six is utilized) until the earliest to occur of (i) repayment/prepayment of any principal amount outstanding under the Additional Bridge Facility, (ii) an insolvency event of any member of the Group, or (iii) acceleration of the Additional Bridge Facility. The Bridge Notes and the Additional Bridge Notes shall be repayable on demand by written notice delivered by the Note Trustee, on a date at least five business days’ following the date of such written notice, provided that such date may not occur before June 16, 2023 (the delivery of such notice, the “Trigger Event”).

The Company has a pre-existing financing relationship with AlbaCore Capital LLP. On November 4, 2021, the Company issued $200,000,000 aggregate principal amount of unsecured notes due 2026 (the “Existing Notes”) to certain affiliates of, or funds managed or advised by, AlbaCore Capital LLP (the “AlbaCore Existing Notes Subscribers”) pursuant to a note subscription agreement (the “Note Subscription Agreement”) and deed poll (the “Deed Poll”) and on March 31, 2022, the Company issued $100,000,000 aggregate principal amount of additional Existing Notes to the AlbaCore Existing Note Subscribers pursuant to a note subscription agreement dated December 23, 2021 and a supplemental deed poll dated March 31, 2022. In addition, the Company has issued warrants (the “AlbaCore Warrants”) to subscribe for Class A ordinary shares, par value $0.001056433113 per share, of the Company (the “Class A ordinary shares”) to the AlbaCore Existing Notes Subscribers pursuant to a warrant instrument dated November 4, 2021, as amended and restated on March 31, 2022 (the “Warrant Instrument”). In connection with, and as a condition subsequent to the execution of the Bridge Facility Agreement, the Company issued Class A ordinary shares representing 2.3% of the share capital of the Company (excluding earnout shares and employee awards) to the AlbaCore Bridge Note Subscribers at par value in a private placement pursuant to a subscription agreement (the “Equity Subscription Agreement”), and amended and restated the Warrant Instrument such that the subscription entitlement of the AlbaCore Existing Notes Subscribers to receive Class A ordinary shares pursuant to the terms of the Warrant Instrument were deemed automatically and irrevocably exercised. The Company issued 105,431 Class A ordinary shares to the AlbaCore Existing Notes Subscribers, pursuant to such deemed exercise of the AlbaCore Warrants, on March 27, 2023.

The Company and AlbaCore Existing Notes Subscribers are expected to enter into a second supplemental deed poll to amend the relevant terms and conditions of the Existing Notes to align with the amendments made to the Bridge Facility Agreement pursuant to the Amendment and Restatement Agreement.

Framework Implementation Agreement

On May 10, 2023, at the same time as the Amended Bridge Facility Agreement was entered into, the Group and AlbaCore entered into a framework implementation agreement (the “Framework Implementation Agreement”) to facilitate a potential restructuring and recapitalization of the Group upon the Trigger Event. The Framework Implementation Agreement contemplates that, upon the Trigger Event, certain direct and indirect subsidiaries of Babylon representing substantially all of the Group’s business and undertaking (the “Go-Forward Business”) will return to private ownership (the “Take Private Proposal”) and provides, subject to specified terms and conditions and definitive documentation, a structure for the following to be implemented: (i) additional funding for the Go-Forward Business; (ii) an amendment of the existing aggregate debt under the Existing Notes, the Bridge Facility, and the Additional Bridge Facility (collectively, the “Debt”), including an extension of the maturity of the Debt; and (iii) a new long-term employee incentive plan.

The proceeds from the Additional Bridge Facility are expected to support the Company’s ongoing operations and facilitate any necessary preparatory work to ensure that the Take Private Proposal can be ready for implementation between June 16, 2023 and June 30, 2023, in the absence of any alternative deliverable proposal from a third party that fully discharges the Group's existing debt and provides sufficient liquidity to support to Group's business, as determined by AlbaCore in its sole discretion. Pursuant to the Take Private Proposal, it is expected that certain assets of Babylon (including the shares of its subsidiary, Babylon Group Holdings Limited) will be sold to a newly formed entity (the “NewCo”) capitalized by AlbaCore and other potential investors (the “Investor Group”). This transaction would be implemented without the approval of Babylon’s shareholders because AlbaCore will be exercising rights under its debt agreements with Babylon and the Take Private Proposal will be implemented through the appointment of administrators by the English courts to Babylon Holdings Limited.

The Framework Implementation Agreement contemplates the implementation of the Take Private Proposal through the appointment of administrators by the English courts to the Company (but not to any other member of the Group) and a series of steps to be described in a steps plan, pursuant to which, the Take Private Proposal will involve (i) the transfer of assets and investments in subsidiaries from Babylon Holdings Limited to Babylon Group Holdings Limited, (ii) a request by the board of Babylon Holdings Limited to the High Court in London for the appointment of administrators to Babylon Holdings Limited; (iii) those administrators’ sale of Babylon Group Holdings Limited and certain other assets of Babylon Holdings Limited (together representing substantially all of the business of the Group) to the NewCo; and (iv) the subsequent dissolution of Babylon Holdings Limited and any subsidiaries in the Group that are not transferred to the NewCo. It is not expected that the Take Private Proposal would involve any financial consideration being provided to Babylon’s Class A ordinary shareholders and holders of equity instruments exercisable for the Class A ordinary shares.

Should the Take Private Proposal proceed, Babylon and AlbaCore are committed to ensuring a smooth, seamless change in ownership of the Go-Forward Business that will not disrupt Babylon's operations or valued employees who are key to reaching profitability. The Go-Forward Business will seek to maintain its partnerships with governments, health providers, employers, and insurers worldwide, and continue to deliver high-quality, cost-effective healthcare through its digital-first platform.

Forward-Looking Statements

This Current Report on Form 8-K (this "Report") contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or our future financial or operating performance. When used in this Report, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, without limitation, information concerning Babylon’s ability to receive available funding from the Additional Bridge Facility in full and its ability to successfully implement the Framework Implementation Agreement, possible or assumed future results of operations, business strategies, debt levels, competitive position, industry environment and potential growth opportunities.

continue as a going concern over the next twelve months; risks associated with our debt financing agreements with AlbaCore, including our ability to receive available funding from the Additional Bridge Facility in full and the impact of the restrictive covenants on our operations; risks associated with the implementation of the Take Private Proposal pursuant to the Framework Implementation Agreement; that we may require additional financing and our ability to obtain additional financing on favorable terms; our ability to timely identify and execute strategic alternatives on favorable terms, including restructuring, refinancing, an asset sale such as the proposed sale of the Meritage Medical Network/Independent Physician Association business, a take private transaction, and/or putting Babylon Holdings Limited into administration under UK law or obtaining relief under the U.S. Bankruptcy Code; risks and uncertainties associated with such administration or bankruptcy proceedings; the diversion of our senior management team’s attention from our business to pursuing strategic alternatives; the impact on our share price as a result of announcements related to a potential take private transaction; turnover in our senior management team and other key talent; our future financial and operating results, ability to generate profits in the future, and timeline to profitability for Babylon as a whole and in our lines of business; the impact of our recently completed reverse share split on the price and trading market for our Class A ordinary shares; if we fail to comply with the NYSE’s continued listing standards and rules, the NYSE may delist our Class A ordinary shares; uncertainties related to our ability to continue as a going concern; our ability to successfully execute our planned cost reduction actions and realize the expected cost savings; the growth of our business and organization; risks associated with impairment of goodwill and other intangible assets; our failure to compete successfully; our ability to renew contracts with existing customers, and risks of contract renewals at lower fee levels, or significant reductions in members, pricing or premiums under our contracts due to factors outside our control; our dependence on our relationships with physician-owned entities; our ability to maintain and expand a network of qualified providers; our ability to increase engagement of individual members or realize the member healthcare cost savings that we expect; a significant portion of our revenue comes from a limited number of customers; the uncertainty and potential inadequacy of our claims liability estimates for medical costs and expenses; risks associated with estimating the amount and timing of revenue recognized under our licensing agreements and value-based care agreements with health plans; risks associated with our physician partners’ failure to accurately, timely and sufficiently document their services; risks associated with inaccurate or unsupportable information regarding risk adjustment scores of members in records and submissions to health plans; risks associated with reduction of reimbursement rates paid by third-party payers or federal or state healthcare programs; risks associated with regulatory proposals directed at containing or lowering the cost of healthcare, including the ACO REACH model; immaturity and volatility of the market for telemedicine and our unproven digital-first approach; our ability to develop and release new solutions and services; difficulty in hiring and retaining talent to operate our business; risks associated with our international operations, economic uncertainty, or downturns; the impact of COVID-19 or any other pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide on our business; risks associated with foreign currency exchange rate fluctuations and restrictions; and the other risks and uncertainties identified in Babylon’s Form 10-K filed with the SEC on March 16, 2023 and Form 10-Q to be filed with the SEC on May 10, 2023, and in other documents filed or to be filed by Babylon with the SEC and available at the SEC’s website at www.sec.gov.

Babylon cautions that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Except as required by law, Babylon does not undertake any obligation to update or revise its forward-looking statements to reflect events or circumstances after the date of this Report.

Item 2.03 Creation of Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth under "Amended and Restated Bridge Facility Agreement" in Item 1.01 of this Current Report is hereby incorporated by reference in this Item 2.03.

Item 7.01 Regulation FD Disclosure.

On May 10, 2023, Babylon issued a press release announcing entry into the Amended Bridge Facility Agreement and the Framework Implementation Agreement. A copy of the press release is furnished as Exhibit 99.1 hereto.

The information contained in this Item 7.01 and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section,

nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits:


Exhibit No.						Description
99.1						Press release, dated May 10, 2023
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 10, 2023


Babylon Holdings Limited

By:			/s/ David Humphreys
Name:			David Humphreys
Title:			Chief Financial Officer

EX-99.1 2 exhibit991pressrelease.htm EX-99.1 Document

Babylon Secures Financing and Plans to Implement a Take Private Transaction with Support from AlbaCore Capital

Austin, Texas and London, UK – May 10, 2023 – Babylon Holdings Limited (NYSE: BBLN) (including its subsidiaries, “Babylon”) is pleased to announce that it has entered into an amendment and restatement of its senior secured term loan facility with AlbaCore Capital LLP and certain of its affiliates (“AlbaCore”), dated March 9, 2023 (the “Bridge Facility Agreement”), for up to an additional $34.5 million in funding (the “Interim Funding”). This investment demonstrates AlbaCore's ongoing support to Babylon. The Interim Funding will be provided on similar pricing terms to the original Bridge Facility Agreement.

The Interim Funding will provide liquidity to support Babylon's operations and enable Babylon to proceed with a proposed longer-term funding and take-private solution under a framework implementation agreement (the “Framework Agreement”) entered into between Babylon and AlbaCore. Under the Framework Agreement, Babylon and AlbaCore expect to proceed with a restructuring and recapitalization that will strengthen Babylon’s balance sheet and provide additional liquidity to deliver on Babylon’s strategic plan. The Framework Agreement contemplates that core operating subsidiaries of Babylon Holdings Limited (the “Go-Forward Business”) will return to private ownership (the “Take Private Proposal”) and is expected to provide, subject to specified terms and conditions and definitive documentation, for: (i) additional funding for the Go-Forward Business; (ii) an amendment of the existing aggregate debt under the original $300 million principal amount of AlbaCore notes due 2026, the notes issued under the Bridge Facility Agreement, and the Interim Funding (collectively, the “Debt”), including an extension of the maturity of the Debt; and (iii) a new long-term employee incentive plan.

Babylon's Board of Directors has approved the Interim Funding and the Take Private Proposal as a constructive step to deliver a longer-term solution to support the Go-Forward Business’s continued path toward profitability, upon consideration of the results of Babylon’s previously announced efforts to explore strategic alternatives, including additional financing and a possible sale of the Meritage Medical Network/Independent Physician Association business (the “IPA Business”).

The Interim Funding will be made available to Babylon in May and early June 2023, subject to the satisfaction of certain conditions precedent. Babylon and AlbaCore plan to implement the Take Private Proposal during June in the absence of other acceptable transaction proposals from third parties in the interim period. It is expected that as part of the implementation of the Take Private Proposal, Babylon Holdings Limited will sell Babylon Group Holdings Limited, which owns Babylon’s core operating subsidiaries that will comprise the Go-Forward Business, to a newly formed entity capitalized by AlbaCore and other investors. This sale will occur without the approval of or any payment to Babylon Holdings Limited’s Class A ordinary shareholders or other equity instrument holders, as AlbaCore will be exercising rights under its debt agreements with Babylon.

Babylon remains focused on its day-to-day operations and patient care, as well as its ongoing and future commercial relationships, and on ensuring stability for Babylon’s key stakeholders. Babylon remains entirely committed to its employees, customers and patients alike, and will proactively seek to maintain and strengthen its partnerships while continuing to provide high-quality, accessible and affordable healthcare through its innovative digital-first platform as Babylon positions itself for its future.

About Babylon

At Babylon, our mission is to make quality healthcare accessible and affordable for every person on Earth. To this end, we are building an integrated digital first primary care service that can manage population health at scale.

Founded in 2013, we are reengineering how people engage with their care at every step of the healthcare continuum. By flipping the model from reactive sick care to proactive healthcare through the devices people already own, we offer millions of people globally, ongoing, always-on care. And, we have already shown that in environments as diverse as the developed UK or developing Rwanda, urban New York or rural Missouri, for people of all ages, it is possible to achieve our mission by leveraging our highly scalable, digital-first platform combined with high quality, virtual clinical operations to provide integrated, personalized healthcare.

Today, we support a global patient network across 15 countries, and operate in 16 languages. In 2021 alone, Babylon helped a patient every 6 seconds, with approximately 5.2 million consultations and AI interactions. Importantly, this was achieved with a 93% user retention rate in our NHS GP at Hand service and 4 or 5-star ratings from more than 90% of our users across all of our geographies. We are working to demonstrate how our model of digital first integrated primary care can be applied to manage the health of the population in different settings across Medicare, Medicaid, and commercial value-based care contracts in the US and our primary care services in the UK.

Babylon is also working with governments, health providers, employers and insurers across the globe to provide them with a new digital-first platform that any partner can use to deliver high-quality healthcare with lower costs and better outcomes. For more information, please visit www.babylonhealth.com.

Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or our future financial or operating performance. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, without limitation, information concerning Babylon’s ability to receive available funding from the Interim Funding in full and its ability to successfully implement the Framework Agreement, possible or assumed future results of operations, business strategies, debt levels, competitive position, industry environment and potential growth opportunities.

These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of Babylon’s management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. These risks, uncertainties, assumptions and other important factors include, but are not limited to: our ability to continue as a going concern over the next twelve months; risks associated with our debt financing agreements with AlbaCore, including our ability to receive available funding from the Interim Funding in full and the impact of the restrictive covenants on our operations; risks associated with the implementation of the Take Private Proposal pursuant to the Framework Agreement; that we may require additional financing and our ability to obtain additional financing on favorable terms; our ability to timely identify and execute strategic alternatives on favorable terms, including restructuring, refinancing, an asset sale such as the proposed sale of the IPA Business, a take private transaction, and/or putting Babylon Holdings Limited into administration under UK law or obtaining relief under the U.S. Bankruptcy Code; risks and uncertainties associated with such administration or bankruptcy proceedings; the diversion of our senior management team’s attention from our business to pursuing strategic alternatives; the impact on our share price as a result of announcements related to a potential take private transaction; turnover in our senior management team and other key talent; our future financial and operating results, ability to generate profits in the future, and timeline to profitability for Babylon as a whole and in our lines of business; the impact of our recently completed

reverse share split on the price and trading market for our Class A ordinary shares; if we fail to comply with the NYSE’s continued listing standards and rules, the NYSE may delist our Class A ordinary shares; uncertainties related to our ability to continue as a going concern; our ability to successfully execute our planned cost reduction actions and realize the expected cost savings; the growth of our business and organization; risks associated with impairment of goodwill and other intangible assets; our failure to compete successfully; our ability to renew contracts with existing customers, and risks of contract renewals at lower fee levels, or significant reductions in members, pricing or premiums under our contracts due to factors outside our control; our dependence on our relationships with physician-owned entities; our ability to maintain and expand a network of qualified providers; our ability to increase engagement of individual members or realize the member healthcare cost savings that we expect; a significant portion of our revenue comes from a limited number of customers; the uncertainty and potential inadequacy of our claims liability estimates for medical costs and expenses; risks associated with estimating the amount and timing of revenue recognized under our licensing agreements and value-based care agreements with health plans; risks associated with our physician partners’ failure to accurately, timely and sufficiently document their services; risks associated with inaccurate or unsupportable information regarding risk adjustment scores of members in records and submissions to health plans; risks associated with reduction of reimbursement rates paid by third-party payers or federal or state healthcare programs; risks associated with regulatory proposals directed at containing or lowering the cost of healthcare, including the ACO REACH model; immaturity and volatility of the market for telemedicine and our unproven digital-first approach; our ability to develop and release new solutions and services; difficulty in hiring and retaining talent to operate our business; risks associated with our international operations, economic uncertainty, or downturns; the impact of COVID-19 or any other pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide on our business; risks associated with foreign currency exchange rate fluctuations and restrictions; and the other risks and uncertainties identified in Babylon’s Form 10-K filed with the SEC on March 16, 2023 and Form 10-Q to be filed with the SEC on May 10, 2023, and in other documents filed or to be filed by Babylon with the SEC and available at the SEC’s website at www.sec.gov.

EX-101.SCH 3 bbln-20230510.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 bbln-20230510_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Tax Identification Number Entity Tax Identification Number Entity Central Index Key Entity Central Index Key Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Entity Ex Transition Period Entity Ex Transition Period Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 bbln-20230510_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	May 10, 2023
Cover [Abstract]
Document Type	8-K
Document Period End Date	May 10, 2023
Entity Registrant Name	Babylon Holdings Limited
Entity Incorporation, State or Country Code	Y9
Entity File Number	001-40952
Entity Address, Address Line One	2500 Bee Cave Road
Entity Address, Address Line Two	Building 1 - Suite 400
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78746
City Area Code	512
Local Phone Number	967-3787
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Class A ordinary shares, par value $0.001056433113 per share
Trading Symbol	BBLN
Security Exchange Name	NYSE
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Amendment Flag	false
Entity Central Index Key	0001866390
Entity Tax Identification Number	98-1638964

XML 7 bbln-20230510_htm.xml IDEA: XBRL DOCUMENT 0001866390 2023-05-10 2023-05-10 false 0001866390 8-K 2023-05-10 Babylon Holdings Limited Y9 001-40952 98-1638964 2500 Bee Cave Road Building 1 - Suite 400 Austin TX 78746 512 967-3787 false false false false Class A ordinary shares, par value $0.001056433113 per share BBLN NYSE true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.babylonhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports bbln-20230510.htm bbln-20230510.xsd bbln-20230510_lab.xml bbln-20230510_pre.xml exhibit991pressrelease.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bbln-20230510.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "bbln-20230510.htm" ] }, "labelLink": { "local": [ "bbln-20230510_lab.xml" ] }, "presentationLink": { "local": [ "bbln-20230510_pre.xml" ] }, "schema": { "local": [ "bbln-20230510.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bbln", "nsuri": "http://www.babylonhealth.com/20230510", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bbln-20230510.htm", "contextRef": "ic387b4284da04023a9eda5c286810e5f_D20230510-20230510", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://www.babylonhealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bbln-20230510.htm", "contextRef": "ic387b4284da04023a9eda5c286810e5f_D20230510-20230510", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.babylonhealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001866390-23-000084-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001866390-23-000084-xbrl.zip M4$L#!!0 ( !LPJE8CA:V>'S -0# 0 1 8F)L;BTR,#(S,#4Q,"YH M=&WM?>E7VTC6]_?GK]#+S#R3G&,9298WZ.8YA"5-=VS2X(0V7W)*4LD6R))' MD@'SU[_WWJK2X@6<=!)(ACFG)UA++;?N\KM+E7[YO[M)J-WP) WBZ-\+#;<0:S@QE&Z4YPE_VZ-ASO!^O>,/"- M-&.1R_/GH8'KRO.W#7K:[':[VW17/>KQHF%J-.5N?13?;,,-''@^Y+LT6-4B M]&]N_]5[=^Z.^83IBR-9&DAUX'C;8:EZ?/V0<0$*XF4ZC++RL!KU0XM@-G6C MHS=,:FZ1_.MV"!.?/V?IGPC&G8JL[_,PMN?MTZB*,,V%8?S*

^]__N=_?LF"+.1[CA-&.C*LT32-7[;%Q5^V1=-.[,WW M?O&"&RW-YB'_=!Z/Z$^XWP?920)7]'^7 MG7'_UZW ;73:#O*KQPP;.F5=[K&F:W5:'=/@3?_3H1I*/J8M+6(3[)H'._L@ MCAZ*Y''(1EN:H!,T>Y?M^,$=]W2?A;@N@0<7O<;'N7,8W[RSSFZ&C=[,NSJZ MN7S;O3J=?+!Z@^-@>']]/[1Z\_[5G_/3P[/@=' YZ1_^/KD75N7\.[EY(/=?_MGH_?VP_WE M<<=X9UW.AQ=NJW]X=#\<0,]6'][?M_IOA_/+BY/FT()_#T^,TXLCZ.-X NW< M>&^/ ^?MA]9PG "X=7 M^_*=C]!7,[H<3(/A1>^N-SFZ[=U_O.I91\;EU?#V]+!_-9Q'BSI7=-4 &@58Q& ML\E!+1E;>\?[[\Z/?MFN+/&W7/&C"#AR?@!+GK#P)/+XW1]\_K+ CRWPW:H% M;C+#Z[8=O=ON@@%R;5]WO+:ML[9K>LU.Q[===VO/ -78:;4:76-IE;>K,IYP MGR<I!TUL M5]L0_1>=RC&D\2RA7V1N=B3O"0;Y$MY3#7%B//4K\/"W'_!$HP'QE7K\X.2/ M*@$77]Y3EZJM3X&^L:=^@2U*LD, ''LX*-UHZF;>5'$O'Z:WYE%U1_U6G6Q7 M"*6HFI-QNZ33MT'S"_5/Y'P,,=>(LBR<[1MWH3#-X(ITR8#GLS 813LNT)LGLC7U@AN'<;+S#X/^M^L#/'VOE@ M?W!T7IW$CS#\\Z.##VGQ_VTRJ=8S8K?CT[.>]@T!A7+J M!#A^2AQQE^,(N'YZ 3AAX(TO+X: (_J3R[='=O_BR!Y:'QK#R8=&[^HL[-TC MCOAH>[_]'EY:X8US%5LPAN;P NR_=1P"'C"&UN7U<# RAX/QU>7 "RX'[KP/ M_9U^[-SUKO;O/K69;S8]E^LMQ^B"?VEU]([K Q3HV$;'==J,&:VMO8[^Q[+Y M7\-(/YDP?"\)MS::%.C>LZ/^0#L[>G]Z-GCV:_!^EJ0S%F5:%FOGW$4?5C,; M6IQH9O.5]_K9CS_VM6S,<>BS),@":/CHSAT#LN7:OIMI<-OL-NS/GL8J /,, M9_\=U.Y[0J%' IM6/7@/KN@3Z'.,K^D>F^MSSA*=1_]M>GIP;7UJ^JS%N&?I M;VNNQN68:-8HX/F.%;:]D-V0!%*DS/HV3 M3'OER=^PZ"&(7J;Q&XR^)G2;/Z ]?G9\]KTFU7IJ+2&B/6=\%*08",WZ<.>_ M3_CM3V:CQ9ECVKK9M4V,P'5UUO!=W3)-WFS9CM'@UM;>&^;,0S"PO\6A!]Y, MJKT+)@$(RL:*X!G(S6K-\.KHCH&Y1<9 A9#D#*&Q5$NGW,5HBJ<%D19DJ08& M&O1#\E^B'S9"%-5@RCK_+F-.R-4K3IQX/-%AZB&;IGQ'_;&K8OXB2Z'32[O5 M#IK0P0U/LL!EH>R$^A.WBY!/W1!AGRR!_SS5L[Q=IUO;F;=\KV'5K49C[6VC M;JZ]]U3-VALUNTV4$-0 @N-J_KK5V%(O3)F'DKUC3>\TL[J((?>7:1Y/JS$U M^;Z.#T._7?0YU#5*5:J+ST4@WK @#&X#]QK%_IL;FI/(C1, %Y1K.\\ ?AS$ MLRA+Y@>Q5P6GF+K;X=Z()=,DOG'%4S\H,!6)B/Y@:%\>?FCV+H['P_M]L_^V M=WMY>&T/8;S]^S_OAU=G5]#O?>]BN)"(B,W^U?BZ/[B^&UX<7_4./QC#^S?7 MIX/QN'=QTN@?]@/H'^;8N[L,,=.T7TU$!%WC\J^QX4X^1NRB.SN] GH<[M_U MK!/[\NW9%=#([EW N*[V39A#$]Z9]R8?;F%>]E_W1_:G;I-U7=YHZ*9M6F ; M3:YW+-;4NU['XZ[7<5J>O[7W.T]2/E^TA#7M )RYB(?:21JRR$O7*M!G+#EK M3";Q+WK:,7BPB78%#FSJ!<(%1V'Z:68:E*5VP>@KA?L==&ES%9V:ST27-K\' M3C\.0@ZM.S##%SWXN!X\>D0/#N_[;X=WO;='C>'@;#*\^O,6VAWW#S]>DQY\ M"[28#._Z@S\;?]U_^.1V6==R64-OM[K@(C2Z;;UK-5JZT6TTFYV&U>*V@\E( MN&=TF];&/L$S9O,UBN\@GDR"%$NX-.1(3;#DBV)X.L4P8'X-K:/_(Z@_.QH"4[-Y5/^S??X1^PO'I6] >5G^"6@*6 MK<&Q?-!NNYYN=UW 2Z*G=SV+:#+Q64XO#IJ7AZ>7?4F M?\*XC\RA=1F>OCTR+Z_> &V\:U0N7<]J=FV[J7?:1A,]L8[.6DY;;_J.Z3$ M)X8'RL5J&H;VAG/M@-UPX"ZV>7SRA?$?9WSKA?&_,^.//IF.[UO,P1H*"D&T M3=U![K=,SBR[9?AMS]C:>S,+*"ZOF9JNG<\"\,[!"GU%"_LB$85$',"?I\D@ MOGV)R7UO>3BZ^]3D5LOOM%P ET8'8"9W=,=VNKK;;G5&.7[,HKYR3';':]K8-$Y!Z?$;+=T9C*FFZ;= MLGV_[3##W]H;_+7()-IG>_,&HN^MK^GX/P#57Y3T1@+X/DXS%EX&4Y%?>1&_ M1\7OD6C 5?^Z!_KW\N+C%=#(&M[_>3>\@GD,AO/^X.SJ=/#!O!S ..Y/Y@C8 M&6^:#6ZV]8Z-&WL:9@/W%MIZHVVV>,-N=!P.TM?NM.W6PS#E.SG"SUB0UL0B M):-CPF6:@)$)IBS4^!UW9UEP@[4,?N#R]/-CDU]?FSTBOOJ%*1ZB]GW#VHL0W4>+WCV*HR]NG M;?8&/>/RJF?W#[UQ?_(Q $QU2R'=KN>V.AT?5#=K@_-IVWJW8^(N\:;=8LVF MZ;4Z6WM-DTA/$X(<]G M^P0<]$.@EN,X 8F3M:T)%9G!3R: (W"0KXD-)YZ68I1""UFJ:N#7LM(V%64^ M33;Y*]6XFT:]V/#[O1?E8,S=:]KYPZ;3) ;HCK543GRG.3R,;W%1\"8NG=;1 M_]#\($09#U(0^(Q''BQ6%L-Z369AQB(>S])PKJ4L"U)_3F_*%V('&)"IDBR\ M42IMGD$[P C17-WSXQ ZQ_>PZ## "H=TYRO5 _](U;]VO=.TOGJ5;M>J=^W. MLZO2->OVD@H3UYZ+!ON&*/(B"3*0)ZSHF44R#Y\N%^(Z<1PZ#(0C Q']@9$F M'@#2&_2O^H=_WEU>7%[UX7IO;6WO_^H]NV[=T-L.+W*:U:(1G=)S,:DEEAWF5N MU::E+;!G,]"PMM64NGUA:RGN*'UEMK6#XS,-9*$.#W[[@I,7[;-6^YS'@&%A M::)1#\P_8(#P1?7\3=6SG$$:?6IPI\&XP<%/Q0"&8V'9B&'K7=;N=@S3\2S? M>E$]#PI!P:G:1++JLMXQ;::;5DGU5+:RYXK'!J1#3[[HGB?4/>\3CJ@'3[:B MTTG0J4A.?1\C:2\ZZ&_IH/D*'60W_:[9MGS=Z[:9#H;7UCO,PH*%3M/K-/UF MJ]M]T4$/"@-PK.Z66/91'&3:GFZ]L _:%J<= MN6/-#5F:?BOM_7/3,6&4;SV?3YPX?/4%M54O5-S:Z\N3=H@9N;)](/6WXP"N M%*KAJPK]ZF3V)/"\D#_1CL!O&5X4JG9N6@X)_P^,CZ$]\W(RO+L<[#_^-3 M:T'U%ZF2_RX>E]I8*.,7!M^ P9>.Z3?,INT91D>W6,O2[7:SJ7<;+5-G;LLR MNFVC;?O^UMZ;-^_Z+XSZ]Y6Q\O/$28-+)S[!77SGAS[IZ?OQ\LE2EMEH M[H M&'K;]FS=MH"K.TV?Z:8+VKO5A47K> ^@%N&<7*MG6>Q>YV[W@^R]T:N-M85 M-1&!/9%S=1)Y&'3@FC/77"HQ@H%= Z;B=$330OU/D&HP1 Z3'2&@'27Q;3;& MV,44:X)8JGGMS2< S&:GS'<^K?.26U^ZG*+LV[7UWFC"6"PB9^T<3&7T^UT#/BO MW6BK*I;6(\'2$I>6OU8RC=. G*6$APSW\*S]?HG:"%*\PIPT#F?9^E>^Z),G MXO_'26'21UQW$LZN=>:#^.VP\);-TZWMI_X*RY*$7^'^7W_^5,K8?T"]8N7V M2ET=+)5ICD$3\Y"[^$' **80V2SE]!1,51:#XE?H3MMJZV;OMWQNPYS M7)MMF.KYP;37YI^4:F\]5XWW--7V)QF?:&;=,+4C/((6Z\]CC6FJ8$T[1(P8 MT&;3_5'"*?^UC,<>K!G_9A.C%G>"#*R!NX'W1Q][!&4'VD\[XVE&GV!]DP0> MJ+5CY@8AZ)EBDE]6%_\LK!-.]C32RM]RJ&GK#G='^-VQ+&-7/D"_S%VT(JCX MYLH^:&UC0; MLRP?L"/&&<;0;T2#]17?Y9W5-$&^'DOG'C M/4NR")?F7>;5Q7*J6^)!/)"_X(91B1M* U_)+\5@58O$:4L<#WUHH61^Y0W' MR8A%(%Y>*64?LEO:>'\4C4)B>!C:%&8$2YT/JS*J]^)F/J('I&4MTUT1:Z;T(% ]3>"*8S03RG. MEP A!UD)+#HKUR6>C.0M*)L2"(P]* )//1\?^S0:/&_ZH# M$2L#*HN+_CQ!;%A-\K7 84M_9OX&=+ /] HULZWP04FGDX[!W[C"0 \8*M"E M4(R+BUEF-R2L-A"OY+Q&QHVV-#)8><"2B?(K 3%X@:BB\B7BF&70ZGVQJ5$L MAUP<^=I#(QC(%P;TP@5U5S C6!GL-)).;JZ,5[U5D^8NEM%5-"(U[57P.E? M,7CC-%+@.E@FL+%Q!*NTGE2YPA"\IQQ\;!6:Q3=&,?2,&D $"29<46^C1E&L M\'/(XGLV0'"I<(#P% \5<0,Y>ES>,1A'5$R;K6Y)>N2+9:P3Q> CH2@RS046 M(APH],QT&@/>HB$Z\RJK49 Z@-ZG2 G4I."4ZL41-UZ0P%HA;PA5[,0L\9 / MU(U4,465>QFT5&QX):U5&D9MP[;2,0M!H0#8@W\R$D&$# G84YCEA-T%DQDI M9[\\UK1&-Z]BS CA75'U, &I !BZR6Q3,8O;>/EM165/D7)Y4>AEX"C)4CEA M&%H+5#S2-5#QH1:RL5\:F]SW0RGYV*7800CV+MVMK%7%HV?Y:02MH0-T3E MM?P2#+%?O+X.3B :K?3SF< " 3)R-P+85=9X"7C(YZ7U1G)PTF%5!V=IX"NP MR?K980KM>Z.4GQ=TK*:U1&(!Z-=B.:5F6W2HA/>#3B70F(,9!U7H$@L+IS&# MIT#9X%D)X-^%+#<:E;ZP#>H/&KW.0=[SB%&!?QF DPE4^,;C>G 4!2PJ$TY( M"ZX0*RGK=2M:%1U\4IQ?P?(O""D84L* 4[!^7-C%XN0;D2]Q>3#-RJ^EL^DT M),U)6DV47Q1Q%+'.$KIA[D!V[,D/QY(MJDEFR+ D$;\#F \6T%[BY>#SE8*' MY\%=35L5EL)C/FY8F"+K+NOPGUBJC[#"<\+QN***_9:H9822B]% M4!XK@G9 M'GJT., D%(PCHK(Z<%3NV*%V[/@3A['LR0/L$JT\[!5;];:38EM$@Z:+>4B M_PHWI+77(DZ/KD$5KW.SF(>-_"2>$%-4U:/XTK&JKEYPK'.ENL Y9EI8_R8 M@L-Y)-4TNH\ $\E;]U;ZU[9V$,8IC@"_NYP#04PRAR+W8,G@-8Y7.%(P%6D4 MJKYU,=J:4L#3&)B\CS-U9O &GJGJL7GN M[ZE/1>=(_>$(_ZX0.H0@WM_A*2#NY_&4:1: NQ7";H/I:#="A8,Q#N!96RFQNO M*I;Z?#%!T/5Y4M*N6:M5K[FY[EVD(\R4"3TA'7*'9[>H,%=Y*OG<5T571#@' MFL=R'^A"?)\>HV\P-5H6M5)??5%H7&7U(SRJ1]"K5FV#"DNS ,F>"8BU0*>R M]D70:%/SFZ>9QZ$D*D(B,- MOUS@X51HAT?D444>9U12AJ@ B(_BY,H-W4Q[A@VMXXH%!B"2VB+"L]>?JVF+836#BLF5_/ 8G_)>J YNG7(L18DH] MP0_BWB#:AL=$NP_.X:%F%Q8DIQ/2#B\AI?W">5WT.;=E M6FJ=__:Y0\W5V)K J0$N MBJICF2)C7[T"#[JU3S("!:68NM5 M??* 3[]Q//+A\( #X$![?_(''0R+O$O)*"V1_LH P_?GI\=GVA3T@>8F')H! M3D3*$;>E@'Z8)^XR,,K_T@0(KFO[(**5AG,7+>P"<#T.Y&0D/.]! MFH;IA!W MY*U8*T%>E7MTW62&SCUP4>!7'@ +I5"7\KL)6!&<3,ELQ:X[(]6&66N PF(! MMJ?YGR)!,5^!HV<9%8KCP#8ALDQA4S(7/$/0O>YJFKBZ=HI?[+T1/&L3B\_-QR ML2R*H8=^]12DI?+V(5Y]#UX1WSD'"WB+N\F6EZID?BOK MA/&'G&M0GZ$XWI!8ADR&^JMKN8&*.?K/#,GSL)*1B[!JK;&IY145-I1L,5&K MW#I2,Q-"F@.6#;B4?%"7(UA8MUK3AX(8*P9)M80>3A4F-\@^ E( M]";&CZG,D;T2%RV# % +W /"6[,;YMIQ;2Z+M33B(4>7H5&P9!?+2EA:U;YN<,&E09=+6-?9R?R["M M5 T,%AZT!P7#1 !VYF:S1(6^'XYPSJ8RC%1Q6X7]VD# :"\ZW"1W292%KVZQ MB"&+(FQ99B%_+,8]U?Z="K"JQOQ8&%9F(J,!:1$CP!XHMI(QRJ>4:?TVUH_C M!)&5]D8^GQ-75"]R(&$DRH(%>HIO<6<=NK65>@V,\;Z7C[Q/8A!^5O6D5&JH M5DYX8)F(W$6PRCH(;RW?&[Q85:>I->;YOHY2$$14[JH5X]X.A:=*_A?ZL^2U MRW=7$&,WCS<5.S@EM7.GO_#WJ$*Z?!IOV:C55AFLV@,!I2*PB$?J,E0*BG IP_HBGA<[Z M=UI($\E065\ 5?'[TP&*7AB _^6I D]%[3AO1>D\63V+?"RR\_/".,&L0<-MS*GNY*X0!0Z\JI8]?+.:Y7 *A3WJVH%G?1PX $:0KXU]['-Q$6- M'@Q;;G$#:0WGXD.,GO 2%_;(\=N#.-? Y6Q+F1I%^7)A.X/H!O.$"[NA3^15 MK;*S'BTDT*.<*[^-9Z&WH'L)R*-G3PPE"T%*A,K%A"BD:E@<,-EX2DT^6D4% MZ=Y1H!4%6&5HD*J"@8H";7(A%'F5METM.?G^@-+ LS%,=S16 \]WF%$H#[B+ M#M@A8LD(/F[D#E(\HV>69.3*K#L4X6?>^_EEN(DOZBIIJU8OUU=8FDHX5 99$+[8F@D[B%EK,:K:#ZK-ICS BB MB%DN0BX4HRG5$4AM(P DRN9$52)48"2IX[7G ;B+HQQR/;QL#\C.;K[S,,9-DI7W5$),%1@\/,$5 M=3'+>GSY/)/\I(7-L'F.QJN,)&E$NEJ!L9O7>1101FW!3)$'+25B[:!$=GM> M7?]*X069*X0MQ.>2F9)BL6@@N'^9K!P^5+5T#[ K:7W%KSB*XE@P/+$%3'FB M\$?^<5BOPH&Y$5@=&2QO.U5_8WI?A&2+ 'RJS /!$L5I:Z*-/S&4X,GE/SONJ M[JGGE',"U1.0>Y)]! ]3>7 ,C%\B![%3GOBJIHWIP!G%NQB EH.BS=BDB!&A M8_EMG(3>+3Q44SXMZ(<9Q2TE:-;&L%;Z?V9,^(%8[Z%SWQ=^GNR)CK919H[ M33!"&*>+?29H-Q$ _MA,_+GA3K&:^KLXIG#&N0KDIC\T%1Y!4Z"-#V8)E7^? MT5?5,7^1?]G[%9UDNR7N;+TF=@.63A5V]R7-0DFS//BMHCT+!_6BW"IU43I8 M]QW\(S\$?L9IXW=^PFZW6=>.U_:BC3A(%=E$45U+D;L916Y4729@FEFB+A:V M Z\+;8 "SA,Z(P#KWTVFO2Z.4/TP>XFPQD3EO/O12?3?D#3\B@&*AA MY8%2S;&,():/G "9 108X>N+>$1:E')2E=TPF#@!#!5%W"!@I/9+D*G(*@T# M83#T(X(DN1=$#3[N1X%K$0,9J=J,X.L,@P)2EH#"LU# V<*NU@I$JDIV,41) MSG,('!A21?UDRC,1>E7)'#IR%G0A "@>W01)'.4YM2* ($^IC2D^,XM(>?S8 M-NHQ7_=A'E2 N[1;%KPA<366C13/NEU!'A+1OC% MWTF0@J;0<#)PYH,C!$"%4$8U[_C=$L)4/J*0S0 MS=*TL$J/ZX*_18!"76 P0*U;F'NT.V2D2F+[DCS]F9.G.6RGBBH1P)=V0J,= M*,+.W8&>ON4HFU1FGNX*)D2FB]V J?@G\<["*3J+@4KE?I6S.0LL]_5,D RX ML6*K_NK]/1AVF"4EZ[%N@I\;P5LLTGC"1^""&1(R>V3XAPP M[?UXG@)^A:;WYE>DM1_9K: S2=95D)(RT'H432OPC(80\B M.O_A#SSME! ]K8.LDPZX7TJ:?JB?UZ'QZ!I# NY<.X@]GK,;V;F27E]B0$&F M:N?0GU.T)X,>.&2QO]X+)#XE@#1+U-E5A7&#=6.3 @QF!'-P85'<*IO],4V. M+"TLTRJ&V*T(G9 K41V)>W^DHA'63R3PX=01T89R"I]O8 CT1*.ZZQJ M4=,I=*>V#DG2BU,62##Q*PIQ34*T$[,!W1B%PB$31/S%4/#U*/B]>QRWON'\'#Z^FO5C*P2('>A0% M/BCLJ$1/DAFYL;66;PI$Y9OP23";J'0GCK48FB?"BPK)YKA=/12'NQ*!"'/@ M: +]O$/'PJ-ZF)U%@DC _2@B*<5.*3ATV7&@&+ M"&R38N782&DF3)(#K($WT&W(M_DF%0:3V;E2M+3,:3E6$'RXBY'K$KT1^Y?T M/BH(E _@"Y4V*X[P+ERN?,T%'Q?B-U_P@D%,/< GS)VK'MR0!;!X8:"FGL>E M2--,I.5>WLF^3@KD^ZJ\0.XRD1J6>,;/IP4J,1Z53Q\7RM3%*J$J$!51GW & M'@%#F$%T702J*A2.P:V'\&[.2'EL/=^O5H@BP_UF\!Z5-PF016P#Y9N)0*,03N53:UN+(LU%//1 MKFDW5AH[G3F3(,WWQV]"D4)ETLH$$P?@@N#WA/@ M)K<"QB ERNJ9Z9L+EG? MYYA%HZ H.;YEQ@?I&@%\?J#K$1X=&5-MD<#?J2Q"Q-1AIH+&4M60ME*,14(% M(RZZ6SPZ;__@5#L[VC_X#5P@L%I@&2=YP1GQ4XPJ)BS5GY5,+"P\)^9'2*!@ M^RQ"?<&CA9P'%8\P=[RD0SQ4JO%4'>% Z@1UM\J M$&OE"2ME%!Z;)L:[L43?I;0$;L-57V\B2ODA^C6LC N*(Q&*4WO$9-;!>^EI M!2+^LQA^HO2':>A_ #X-RR[H^=%!L;VC4N&F7OE3'02[YL5*P;3$GC12I852 M^:HX,CIO"4^V*9^YKQHEJYC[ZS*1#C?RN=QR)PW$/M_;V]MZRMWZ*+YY])N$ ME1#+^J^6/1))_;S&OG<01A'495*.\TH$9$$!9 5,]HLPGBI>H -,Y %$>0-8 M&HD:51;[T'XP-(ID)<$Z(S2B\FTJ8U@;<:S)*&DZ)8G#O?.L>M8;;E6IXV?- M^#3#>_F!D< GX H7F7,-_;+B;3GLA_F\4]+676CH1W LBK3>BCJZ8]S MO_6TH*3X)$7I@H!#>,WW]3

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